Article about NEU competitors still in the race for Rett treatment.
Rett failure sets up thin pipelinehttps://www.evaluate.com/vantage/articles/news/trial-results/rett-failure-sets-thin-pipeline
Phase III pipeline for Rett treatment includes Trofinetide (Acadia), Anavex 2-73 (Anavex), Epidiolex (GW Pharmaceuticals). Indicated sales for each treatment ($US126m for Trofinetide) shown in article are less than I was expecting.
Article about NEU competitors still in the race for Rett...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.95 |
Change
0.610(2.86%) |
Mkt cap ! $2.801B | |||
| Open | High | Low | Value | Volume |
| $21.50 | $22.27 | $21.49 | $7.556M | 345.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 158 | $21.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.94 | 21 | 1 |
View Market Depth
| Last trade - 12.36pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.92 |
Change
0.610 ( 2.60 %) |
||||
| Open | High | Low | Volume | ||
| $21.56 | $22.26 | $21.50 | 90579 | ||
| Last updated 12.55pm 16/05/2024 ? | |||||
| NEU (ASX) Chart |